Stay updated with breaking news from Decipher Prostate Genomic Classifier. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Veracyte, Inc. , a leading cancer diagnostics company, today announced that a new study published in JCO Precision Oncology shows that, among patients undergoing Active Surveillance for prostate...
Veracyte, Inc. , a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene expression test to receive a “Level 1B” evidence rating in...
Veracyte, Inc. (NASDAQ: VCYT) shares spiked heading into the Thanksgiving long weekend, after the company announced that seven posters will be presented at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023), where they will demonstrate ...
Grew Total Revenue to $90.1 million, an Increase of 19% Grew Testing Revenue by 27% Conference Call and Webcast Today at 4:30 p.m. ET ...
Veracyte, Inc. (NASDAQ:VCYT) shares are volatile after-hours on Wednesday after the company announced that new data from a phase 3 trial validates...